ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2727

Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis

Bhargavi Duvvuri1, Lauren Pachman 2, Richard Moore 1, Gabrielle Morgan 2, Marisa Klein-Gitelman 2, Megan L. Curran 3, Stephen Doty 4 and Christian Lood 1, 1University of Washington, Seattle, 2Northwestern University, Chicago, 3University of Colorado, Aurora, CO, 4Hospital for Special Surgery, New York

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: anti-mitochondria antibody and calcinosis, juvenile dermatomyositis, Mitochondria, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T047: Plenary III (2727–2732)

Session Type: Plenary Session III

Session Time: 11:00AM-12:30PM

Background/Purpose: Though mainly found intracellularly, we recently observed mitochondrial extrusion upon cell death, contributing to inflammation and organ damage in lupus-prone mice. Of note, mitochondria are immunogenic, promoting development of anti-mitochondrial antibodies (AMAs). Mitochondrial remnants, including DNA, are observed in the circulation of many systemic diseases, including lupus, and thought to partake in the disease pathogenesis. However, the role of mitochondrial extrusion in children with juvenile dermatomyositis (JDM) has not been addressed. The aim of this study was to investigate markers of mitochondrial extrusion, including mtDNA and AMAs, in JDM children to determine their clinical utility.

Methods: AMAs, as well as cell-free mtDNA levels were analyzed in healthy children (HC, n=22), pediatric lupus (n=10), polymyositis (n=7), JDM patients (n=61), and RNP+ myositis (12), by a state-of-the-art flow cytometry technique as well as an in-house qPCR assay. Mitochondrial markers were associated with disease activity score (DAS), calcinosis, as well as autoantibody profiles. Muscle biopsies were analyzed using electron microscopy.

Results: Electron microscopy imaging demonstrated profound mitochondrial abnormalities in JDM muscle, including intramitochondrial calcification associated with degenerate muscle fibers and mitochondrial extrusion. As compared to healthy controls, JDM patients had increased levels of cell-free mtDNA (p=0.02) but not genomic DNA (p=0.09) in peripheral blood, especially in children with calcinosis (p=0.002). As determined by Western blot, JDM patients had autoantibodies reacting towards mitochondrial antigens of 60 kDa, similar to what was seen in jSLE. By flow cytometry, 40% of JDM patients were found to be positive for AMAs (p< 0.001). Consistent with the immunogenic nature of mitochondria, AMA levels correlated with presence of antigen, e.g. mtDNA, in peripheral blood (r=0.28, p< 0.05), as well as with immune complex (IC) levels (r=0.56, p< 0.0001) and complement C4 consumption (r=-0.59, p=0.01). Upon activation with mitochondrial ICs, neutrophils induced IL-8 production (p< 0.01) as well as underwent formation of neutrophil extracellular traps (NETs, p< 0.05), clearly demonstrating the inflammatory potential of mitochondrial ICs. AMA positivity was associated with calcinosis (OR=6.1, p=0.006). Of importance, AMA became elevated prior to the clinical diagnosis of calcinosis (OR=11.1, p< 0.05), with a sensitivity and specificity of 80% and 73.5%, respectively, to identify calcinosis-prone individuals within the group of children with JDM, suggesting a prognostic potential of AMA in JDM calcinosis development. Conclusion: JDM patients have obvious mitochondrial abnormalities in tissue and periphery. Our novel findings of mitochondrial antibodies in JDM, preceding clinical diagnosis of calcinosis, support i) mitochondrial extrusion as a potential therapeutic targetable pathway, and ii) the use of AMAs as prognostic markers, allowing for early, preventive treatment, reducing development of disabling calcinosis in those children.


Disclosure: B. Duvvuri, None; L. Pachman, Reveragen, 2, SBIR grant Eric P. Hofffman, PhD RevaraGen, unrelated.,, 9; R. Moore, None; G. Morgan, None; M. Klein-Gitelman, None; M. Curran, None; S. Doty, None; C. Lood, None.

To cite this abstract in AMA style:

Duvvuri B, Pachman L, Moore R, Morgan G, Klein-Gitelman M, Curran M, Doty S, Lood C. Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mitochondrial-contribution-to-juvenile-dermatomyositis-pathogenesis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mitochondrial-contribution-to-juvenile-dermatomyositis-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology